Plain-English translation of NCT06498414 on ClinicalTrials.gov ↗ · Source last updated · Translation generated ·
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing three different antibiotic regimens to prevent tuberculosis infection in people who have tested positive for TB exposure but do not currently have active disease. The researchers are comparing a standard 4-month course of rifampin with two shorter experimental options: a 2-month higher-dose rifampin regimen and a 1-month combination of . The goal is to find treatments that work just as well but are easier to complete, with fewer side effects.
Standard TB preventive treatment takes 4 months or longer, and many patients struggle to finish the full course. This trial is designed to find shorter treatment options that are safer and easier to complete, which could help more people successfully prevent tuberculosis disease from developing.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be assigned to take one of three antibiotic regimens daily by mouth for either 1, 2, or 4 months. You will take your medication at home on your own schedule. You'll have regular check-ins with the research team to monitor how you're tolerating the treatment, report any side effects, and have blood tests done to ensure your liver and blood cells are healthy. The entire study lasts several months depending on which treatment group you're in.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Benin
Brazil
Canada